SHERIDAN, WYOMING - April 13, 2026 - The conclusion of EU-India Free Trade Agreement negotiations delivers a structural shift for medical technology trade, eliminating tariffs on the vast majority of EU-manufactured medical devices entering India - duties that historically reached as high as 30% on certain product categories. MedTech Europe, the European medical technology industry association, engaged directly with the European Commission throughout the negotiating process, providing technical input to shape a workable framework. The agreement's tariff eliminations, trade facilitation provisions, and new regulatory cooperation mechanisms collectively reposition the EU-India medical device corridor as a lower-friction, higher-volume trade channel.
Tariff elimination and its market access effect
EU-manufactured medical devices exported to India have long carried some of the sector's most significant third-country duty burdens, with rates reaching up to 30% depending on product classification. The FTA eliminates these duties across the vast majority of device categories, directly reducing landed cost for European manufacturers competing in the Indian market. That cost reduction translates into improved price competitiveness against domestically produced devices and imports from non-FTA jurisdictions.
India's medical device market has grown rapidly, driven by expanding hospital infrastructure, rising chronic disease burden, and government-backed healthcare access programs. EU manufacturers previously absorbed or passed on high import duties, compressing margins or limiting addressable segments. Tariff elimination now opens pricing headroom that can be redirected toward distributor incentives, market development, or price-competitive positioning in public procurement tenders.
Regulatory and customs provisions
Beyond tariffs, the agreement incorporates provisions on customs procedures and trade facilitation designed to reduce administrative friction at the border. Transparency requirements and commitments to good regulatory practices are embedded in the text, creating a framework that should limit arbitrary or unpredictable regulatory decisions affecting device approvals and market entry timelines.
A dedicated Working Group on Conformity Assessment represents one of the agreement's most operationally significant elements for the sector. This body creates a structured bilateral mechanism for addressing divergence between EU and Indian conformity assessment requirements - a persistent source of duplication and cost for manufacturers seeking approval on both sides. Over time, this working group could reduce the testing and documentation burden currently required to achieve dual-market compliance.
MedTech Europe's role and implementation outlook
MedTech Europe maintained active engagement with the European Commission across the negotiating period, contributing technical expertise to ensure that sector-specific concerns - including conformity assessment alignment and regulatory transparency - were reflected in the final text. That advocacy role now shifts toward implementation support, with the association committing to facilitate practical application of the agreement across its member companies.
Implementation timelines and the sequencing of tariff phase-downs or eliminations will determine how quickly manufacturers can build these advantages into their India market strategies. MedTech Europe's continued involvement with the European Commission and Indian regulatory counterparts will be critical for resolving interpretive ambiguities and ensuring that commitments on customs facilitation and regulatory practices translate into actual processing improvements at the point of entry.
Business impact
Export and market access managers at EU medical device manufacturers must now rebuild India pricing models to reflect the elimination of duties that previously reached 30%. Companies that de-prioritized India due to cost-of-entry constraints should re-evaluate market entry or expansion plans for their 2026-2027 budget cycles, incorporating revised landed-cost assumptions and updated competitive positioning against non-FTA suppliers that still face full duty exposure.
Regulatory affairs and compliance teams face an immediate action item: tracking the Working Group on Conformity Assessment as it becomes operational. Decisions made in that forum will determine whether EU conformity documentation carries any equivalence weight in Indian approval processes - directly affecting the cost and timeline of dual-market registration strategies. Procurement leads sourcing EU-manufactured devices for cross-border distribution into India should factor lower duty costs into long-term supplier contract negotiations, and supply chain officers should assess whether the FTA shifts the economics of regional distribution hub placement between EU and non-EU origin points.